Metabolomics combined with network pharmacology reveals mechanism of Jiaotai Pills in treating depression.
10.19540/j.cnki.cjcmm.20241107.705
- Author:
Guo-Liang DAI
1
;
Ze-Yu CHEN
2
;
Yan-Jun WANG
1
;
Xin-Fang BIAN
1
;
Yu-Jie CHEN
1
;
Bing-Ting SUN
3
;
Xiao-Yong WANG
1
;
Wen-Zheng JU
1
Author Information
1. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, China.
2. School of Pharmacy,Xuzhou Medical University Xuzhou 221004, China.
3. Department of Pharmacy, Nanjing Hospital of Chinese Medicine Nanjing 210022, China.
- Publication Type:Journal Article
- Keywords:
Jiaotai Pills;
depression;
metabolomics;
network pharmacology
- MeSH:
Animals;
Drugs, Chinese Herbal/chemistry*;
Depression/genetics*;
Mice;
Network Pharmacology;
Metabolomics;
Male;
Disease Models, Animal;
Humans;
Protein Interaction Maps/drug effects*;
Antidepressive Agents
- From:
China Journal of Chinese Materia Medica
2025;50(5):1340-1350
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to explore the mechanism of Jiaotai Pills in treating depression based on metabolomics and network pharmacology. The chemical constituents of Jiaotai Pills were identified by UHPLC-Orbitrap Exploris 480, and the targets of Jiaotai Pills and depression were retrieved from online databases. STRING and Cytoscape 3.7.2 were used to construct the protein-protein interaction network of core targets of Jiaotai Pills in treating depression and the "compound-target-pathway" network. DAVID was used for Gene Ontology(GO) function and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analyses of the core targets. The mouse model of depression was established with chronic unpredictable mild stress(CUMS) and treated with different doses of Jiaotai Pills. The behavioral changes and pathological changes in the hippocampus were observed. UHPLC-Orbitrap Exploris 120 was used for metabolic profiling of the serum, from which the differential metabolites and related metabolic pathways were screened. A "metabolite-reaction-enzyme-gene" network was constructed for the integrated analysis of metabolomics and network pharmacology. A total of 34 chemical components of Jiaotai Pills were identified, and 143 core targets of Jiaotai Pills in treating depression were predicted, which were mainly involved in the arginine and proline, sphingolipid, and neurotrophin metabolism signaling pathways. The results of animal experiments showed that Jiaotai Pills alleviated the depression behaviors and pathological changes in the hippocampus of the mouse model of CUMS-induced depression. In addition, Jiaotai Pills reversed the levels of 32 metabolites involved in various pathways such as arginine and proline metabolism, sphingolipid metabolism, and porphyrin metabolism in the serum of model mice. The integrated analysis showed that arginine and proline metabolism, cysteine and methionine metabolism, and porphyrin metabolism might be the key pathways in the treatment of depression with Jiaotai Pills. In conclusion, metabolomics combined with network pharmacology clarifies the antidepressant mechanism of Jiaotai Pills, which may provide a basis for the clinical application of Jiaotai Pills in treating depression.
